Paid Clinical Trials South Dakota

Discover 349 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 349

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting

PHASE1

PHASE2

Sponsor:

Takeda

Location:

Sioux Falls, Minneapolis, Aurora, Indianapolisshow 7 more

Code:

NCT04844073

Conditions

Squamous Cell Cancer of Head and Neck (SCCHN)

Non-small Cell Lung Cancer (NSCLC)

Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-186

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Recruiting

PHASE3

Sponsor:

Melt Pharmaceuticals

Location:

Sioux Falls, W. Fargo, Fargo, Alexandriashow 8 more

Code:

NCT06383273

Conditions

Cataract

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

MELT-300 sublingual tablet

Midalozam sublingual tablet

Placebo sublingual tablet

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Sioux Falls, Winnipeg, Denver, Arvadashow 121 more

Code:

NCT06268873

Conditions

Chronic Kidney Disease and Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baxdrostat/dapagliflozin

Dapagliflozin in combination with placebo

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting

PHASE3

Sponsor:

Sanofi

Location:

Fargo, Plymouth, Minneapolis, Fort Collinsshow 78 more

Code:

NCT06141473

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Teriflunomide

Placebo infusion

Placebo tablet

MRI contrast-enhancing agents

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Recruiting

PHASE2

Sponsor:

Fujifilm Pharmaceuticals U.S.A., Inc.

Location:

Sioux Falls, Westwood, Madison, Saint Louisshow 16 more

Code:

NCT05318573

Conditions

Advanced Urothelial Carcinoma

Advanced Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

FF-10832

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Jamestown, Fergus Falls, Fargo, Willmarshow 350 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Recruiting

PHASE2

Sponsor:

SWOG Cancer Research Network

Location:

Jamestown, Fergus Falls, Fargo, Grand Islandshow 210 more

Code:

NCT05040360

Conditions

Metastatic Malignant Neoplasm in the Liver

Pancreatic Neuroendocrine Tumor

Stage I Pancreatic Neuroendocrine Tumor AJCC v8

Stage II Pancreatic Neuroendocrine Tumor AJCC v8

Stage III Pancreatic Neuroendocrine Tumor AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Capecitabine

Temozolomide

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Sioux Falls, Fargo, Grand Forks, Lincolnshow 33 more

Code:

NCT06077760

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

V940

Pembrolizumab

Placebo

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Sioux Falls, Bismarck, Rapid City, Worthingtonshow 395 more

Code:

NCT04181060

Conditions

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

Stage IIIB Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bevacizumab

Biospecimen Collection

Computed Tomography

Echocardiography

Magnetic Resonance Imaging

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Recruiting

PHASE3

Sponsor:

Novo Nordisk A/S

Location:

Sioux Falls, Rapid City, Omaha, Minneapolisshow 157 more

Code:

NCT05636176

Conditions

Heart Failure

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ziltivekimab

Placebo